Grace Therapeutics, Inc.: Form 10-K for the period ended Mar 31, 2024
Filed with the SEC on Jun 21, 2024 and accepted by EDGAR at Jun 21, 2024, 07:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2023-04-01 to 2024-03-31 | $4.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2023-04-01 to 2024-03-31 | −$12.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2023-04-01 to 2024-03-31 | −$1.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2023-04-01 to 2024-03-31 | −$12.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-04-01 to 2024-03-31 | −$1.35 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-04-01 to 2024-03-31 | −$1.35 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-04-01 to 2024-03-31 | 9,529,123 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-04-01 to 2024-03-31 | −$12.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-03-31 | $23.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-31 | $24.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-31 | $73.3m | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $1.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-03-31 | $11.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-03-31 | $61.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-075875. Last ingested by Listed: Oct 26, 2026, 18:07 ET. Listed shows no prices and gives no investment advice.